Table 4 Clinical features of CLL samples analysed by data dependant acquisition (DDA) to generate a CLL-specific spectral library for mapping data acquired by SWATH-MS.
Sample | Gender | IGHV % | Chromosomal abnormalities | Prior therapy (Y/N) | WBC (109/l) | Lymphocyte count (109/l) | % viable cells after thaw |
|---|---|---|---|---|---|---|---|
CLL-1 | F | 5.9 | 13q− | N | 63.5 | 63.4 | 88 |
CLL-2 | M | IGHV failed to identify single dominant clone 5 different clones identified 0–12 | 13q−, 11q− | N | 21.7 | 15.5 | 90 |
CLL-3 | M | NA | 17p− | Y | 48.1 | 45 | 78 |
CLL-4 | M | NA | 13q− | Y | 24.1 | 21.9 | 87 |
CLL-5 | M | 2.08 | 13q− | N | 144.3 | 137 | 80 |
CLL-6 | M | NA | 17p−, 13q− | Y | 49.2 | 44.7 | 82 |
CLL-7 | M | 0 | Normal | Y | 65.4 | 63.3 | 84 |
CLL-8 | M | NA | 13q− | Y | 110.2 | 102.9 | 90 |
CLL-9 | F | 0 | Normal | Y | 52.7 | 46.7 | 96 |
CLL-10 | F | NA | 13q− | N | 149.9 | 144.8 | 88 |
CLL-11 | F | 0 | Normal | Y | 31.3 | 27.9 | 92 |
CLL-12 | M | 0 | 17p− | Y | 291.6 | NA | 70 |
CLL-13 | M | NA | 17p−, 13q− | Y | 246.4 | NA | 77 |
CLL-14 | F | 5.9 | 11q−, 12+ | Y | 19.3 | 17.4 | 90 |
